Virax Total Liab from 2010 to 2024

VRAX Stock  USD 1.94  0.06  3.19%   
Virax Biolabs Total Liabilities yearly trend continues to be fairly stable with very little volatility. Total Liabilities will likely drop to about 327.9 K in 2024. Total Liabilities is the total amount of all liabilities that Virax Biolabs Group has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2010-12-31
Previous Quarter
345.2 K
Current Value
327.9 K
Quarterly Volatility
322.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 97.9 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 8.96, Dividend Yield of 0.0 or PTB Ratio of 0.29. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Latest Virax Biolabs' Total Liab Growth Pattern

Below is the plot of the Total Liab of Virax Biolabs Group over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Virax Biolabs' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Virax Total Liab Regression Statistics

Arithmetic Mean1,071,714
Geometric Mean996,009
Coefficient Of Variation30.07
Mean Deviation244,519
Median1,237,733
Standard Deviation322,226
Sample Variance103.8B
Range917.5K
R-Value(0.72)
Mean Square Error54.5B
R-Squared0.51
Significance0
Slope(51,567)
Total Sum of Squares1.5T

Virax Total Liab History

2024327.9 K
2023345.2 K
2022908.4 K
20211.2 M
2020871.4 K

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Liabilities345.2 K327.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.